Lupin stock analysis 2014
Lupin stock short term technical view
Lupin stock on last trading session closed at 1379 with gain. On daily chart, stock is in absolute uptrend and making higher tops and bottom. On chart, stock just tested its month average and moving upside suggesting fresh upside for new short term high. 1330 is 1-month average and below it, 1235 is major short-term support of 3-month average. On upside 1421 and 1480 are strong resistances as well as targets for short-term traders. Daily chart indicators are bullish and suggesting fresh bottom out pattern for prices so stay long with stop loss below 1330 for target 1421 and then 1480.
Lupin stock medium term technical view
Lupin stock this week closed with loss. On weekly chart stock price trend and momentum both are strong bullish. On weekly chart indicator pattern are bearish and with topped out pattern but price is still way above major average so in medium term expect correction here and limited upside. From medium term view, 1280 and 1065 are strong support. Above 1065, swing traders and medium term investors must keep buy on dips view. On upside 1495 and 1705 are strong resistances as well as medium term targets. These targets are expected in next 6 to 12 months period. Any weekly closing below1065 means medium term change and start of downcycle for stock price so medium term traders must keep strict stop loss below it for there medium term investment in this stock.
Lupin stock long term technical view
Lupin stock this week in last 6 month had given almost 50% returns while nifty and sensex had given 19% return. Clear out performance in this pharma stock. From long term view, above 940-rupee level stock will remain bullish and buy on dips. On upside 1315 was first target which is already achieved and if sustain above it for 3-4 weeks then 1615 is next target for stock in next 12 to 24 month period. On monthly chart this will be forth, gaining month for stock price and in these 4-month stocks rallied from 900 rupee to 1400 rupees. On downside 560 was best buying level, which was lasts seen in 2012 while 200 rupee was undervalued level which was lasts seen in 2003.
Lupin company description
Lupin Limited is a transnational pharmaceutical company. The Company produces a range of generic and branded formulations and bulk drugs. The Company along with its subsidiaries has manufacturing locations spread across India and Japan with trading and other incidental and related activities extending to world markets. The Company’s product basket consists of formulations from Cephalosporins, CVS, CNS, Anti-Asthma, Anti-TB, Diabetology, Dermatology, GI, and other therapy segments . The Company’s products include Cephalexin, Cefaclor, Ethambutol, Prasugrel, Rasagiline Mesylate, Lacosamide, and Febuxostat. Its brands include AKT 2, AKT3, AKURIT3, BUDAMATE 100 TRANSCAPS, BUDAMATE 100 HFA TRANSHALER, BUDATE 100 HFA TRANSHALER (MDI), and BUDATE 200 HFA TRANSHALER (MDI). The Company’s Drugs and products reach over 100 countries in the world. Effective February 2014, Lupin Ltd acquired Nanomi BV, a manufacturer of pharmaceutical products.
Lupin stock fundamental ratio
|52 week||840.40 – 1,442.15|